MV CAPITAL MANAGEMENT, INC.
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 1633366
BETHESDA, MD
Position in APLS
as of Mar 31, 2026
· filed Apr 30, 2026
Position Value
$0
+$0 QoQ
Shares Held
6
-33.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MV CAPITAL MANAGEMENT, INC. holds $228,442 across 29 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
210 | $104,313 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
61 | $38,035 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
66 | $19,867 | |
| 4 | INCY |
Incyte Corp
|
113 | $12,809 | |
| 5 | MRNA |
Moderna, Inc.
|
124 | $8,683 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
90 | $7,335 | |
| 7 | RPRX |
Royalty Pharma plc
|
124 | $6,952 | |
| 8 | CYTK |
Cytokinetics Inc
|
71 | $6,048 |
All Filings in APLS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 6 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | — | 9 | Shares | Sole | 2026-02-23 | |
| 2025-09-30 | — | 8 | Shares | Sole | 2026-02-23 | |
| 2025-06-30 | — | 8 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | — | 6 | Shares | Sole | 2025-04-15 | |
| 2024-12-31 | — | 29 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | — | 4 | Shares | Sole | 2024-11-04 | |
| 2024-06-30 | — | 2 | Shares | Sole | 2024-08-01 | |
| No filing history on record for this holder in this stock. | ||||||